Preview

Rational Pharmacotherapy in Cardiology

Advanced search

QUALITY OF LIFE AND COMPLIANCE TO THERAPY IN PATIENTS FOLLOWING SUCCESSFULTRANSLUMINAL CORONARY ANGIOPLASTY, WHO WERE PRESCRIBED FLUVASTATIN EXTENDED RELEASE ADDED TO STANDARD THERAPY. PROTOCOL OF THE OPEN-LABEL OBSERVATIONAL STUDY

https://doi.org/10.20996/1819-6446-2010-6-3-345-348

Full Text:

Abstract

Aim. To evaluate quality of life changes and compliance to therapy in patients following successful transluminal angioplasty, who have indications for fluvastatin extended release in addition to standard treatment.

Material and methods. This is a national observational multicenter study. An inclusion of 60 investigator centers is planned (out-patient medical centers), the total number of patients to be included is 600. Patients (men and women) with coronary heart disease following successful transluminal coronary angioplasty, who were prescribed fluvastatinextended release (Lescol Forte, Novartis) 80 mg once daily will be included in the observation. The following efficacy and safety parameters will be evaluated: quality of life assessed with SF-36 scale before and during treatment; compliance to therapy; adverse events and serious adverse events. Observation period is planned for 6 months. During this period patient is expected to make 4 visits to treating physician. According to the physician’s decision, observation period can be extended to 12 months.

Present study status. The study is completed. 524 patients completed the observation, including 116 patients who were followed up for 12 months. There are 414 men (79%) and 110 women (21%) among patients enrolled into the study.

About the Authors

A. V. Susekov
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


V. A. Bulatov
Novartis Pharmaceuticals
Switzerland
WSJ-27.4.37, CHBS-4002, Basel


A. V. Vigdorchik
Novartis Pharma
Russian Federation
Sadovnicheskaya ul. 82, stroen. 2, Moscow, 115035


References

1. Оганов Р.Г., Масленникова Г.Я. Смертность от сердечно-сосудистых и других хронических неинфекционных заболеваний среди трудоспособного населения России. Кардиоваск тер и профил 2002; 3: 4-8.

2. Hamm C.W., Heeschen C., Falk E., Fox K.A.A. Acute Coronary Syndromes: Pathophysiology, Diagnosis and Risk Stratification. In Camm AJ, Luscher T, Serruys PW (eds): The ESC Textbook of Cardiovascular Medicine. Oxford: Blackwell Publishing Ltd; 2006. Р. 333-365.

3. Здоровье населения России и деятельность учреждений здравоохранения в 1998 г. (статистические материалы). М., 1999.

4. Здравоохранение в России. 2005. Статистический сборник. М.: Росстат; 2006.

5. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case￾control study. Lancet 2004; 364 (9438):937-52.

6. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.

7. Sacks F.N., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. Cholesterol and Recurrent Events Trial investigators. N EnglJ Med 1996; 335(14):1001-1009.

8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934):1383-1389.

9. Serruys P.W., de Feyter P., Macaya C. et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287(24): 3215-3222.

10. Pitt B., Waters D., Brown W.V. et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341(2): 70-76.

11. Сусеков А.В., Зубарева М.Ю., Рожкова Т.А., Кухарчук В.В. Лескол и коронарный атеросклероз: по результатам трех контролируемых исследований (LCAS, FLARE, LIPS). Международный мед журн 2002; 5(3): 225-233.

12. Robinson J.G., Smith B., Maheshwari N., Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46(10):1855-62.

13. Boden W.E., O'rourke R.A., Teo K.K. et al. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics ofthe Clinical Outcomes Utilizing Revascularization andAggressiveDruG Evaluation (COURAGE) trial. Am J Cardiol 2007; 99(2):208-12.

14. Maron D.J., Boden W.E., O’Rourke R.A. et al. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Agressive Drug Evaluation) trial. J Am Coll Cardiol 2010; 55(13): 1348-58.

15. Алекян Б.Г. Эндоваскулярная хирургия заболеваний сердца и сосудов: современное состояние и перспективы развития. Российские медицинские вести 2004; 4: 65-68.

16. Gibbons R.J., Chatterjee K., Daley J. et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina).J Am Coll Cardiol 1999; 33(7): 2092-2197.

17. Spertus J.A., Nerella R., Kettlekamp R. et al. Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery. Circulation 2005; 111(6): 768-773.

18. Spertus J.A., Salisbury A.C., Jones P.G. et al. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation 2004; 110(25): 3789-3794.

19. Krumholz H.M., McHorney C.A., Clark L. et al. Changes in health after elective percutaneous coronary revascularization. A comparison of generic and specific measures. Med Care 1996; 34(8): 754-759.


For citation:


Susekov A.V., Bulatov V.A., Vigdorchik A.V. QUALITY OF LIFE AND COMPLIANCE TO THERAPY IN PATIENTS FOLLOWING SUCCESSFULTRANSLUMINAL CORONARY ANGIOPLASTY, WHO WERE PRESCRIBED FLUVASTATIN EXTENDED RELEASE ADDED TO STANDARD THERAPY. PROTOCOL OF THE OPEN-LABEL OBSERVATIONAL STUDY. Rational Pharmacotherapy in Cardiology. 2010;6(3):345-348. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-3-345-348

Views: 213


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)